Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...

Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...

Most of my life I have been pretty stoic about getting injections or blood draws and even as a child I wasn’t bothered by ...

Roche's Perjeta has been launched today in the UK for use in women with HER2-positive breast cancer before surgery – but, as with many new cancer drugs, access to treatment is uncertain.

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...

Perjeta has become one of Roche’s fastest-growing and top-selling drugs, thanks in no small part to data from the APHINITY trial which showed that adding it to Herceptin can improve disease-free ...

Despite everything I still feel very, very lucky. I have enough to cover my upcoming four rounds of Perjeta immunotherapy thanks to the generosity of friends and strangers. If not for that I would ...

Phesgo is the combined therapy of Perjeta, Herceptin and ENHANZE, which is given in a single seven-minute subcutaneous injection for the treatment of breast cancer. We believe Phesgo is an ...

And it’s important to note that in this space, in the breast cancer space, the largest drugs by far are infused drugs, whether it’s in HER2, Herceptin, PERJETA in the HER2 positive space or in ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2024 Earnings Call Transcript February 18, 2025 Halozyme Therapeutics, Inc. beats earnings expectations. Reported EPS is $1.26, expectations were $1.17 ...